UNSPSC 51411609: Teopranitol

This classification denotes a vasodilating agent with the molecular formula C16H22N6O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 631R1KON85, chemically known as 1,4:3,6-dianhydro-2-deoxy-2-((3-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurin-7-yl)propyl)amino)-l-iditol 5-nitrate but generally known as teopranitol, which bears US NIH Compound Identifier 3034007. European Medicines Agency schedules Teopranitol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10902MIG.

UNSPSC 51411609 Teopranitol is a Commodity code representing pharmaceutical products procured by state and local governments, primarily through emergency medical services, health agencies, and cooperative purchasing alliances. State and local buyers under this code are acquiring advanced life support medications, generic multi-source pharmaceuticals, and OTC products for distribution across government facilities, emergency response operations, and pharmacy benefit programs. Issuing bodies span city fire departments, state health and human services agencies, and multistate cooperative purchasing organizations—Tampa Fire Rescue via the City of Tampa's Purchasing Department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the recent mix. Scope includes sealed competitive bidding for specific medication line items with firm pricing, inventory management requirements (expiration-date warranties, replacement logistics), regulatory compliance (FDA approval, cGMP certification, Drug Supply Chain Security Act adherence), and accessibility and safety documentation (WCAG 2.2 conformance, OSHA Safety Data Sheets).

Recent activity concentrates in Florida, Texas, and Minnesota, with national reach through cooperative purchasing platforms. The City of Tampa issued IFB 26P00188 in April 2026 for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials—with a response deadline of April 8, 2026 and an estimated contract value of $40,000, featuring a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring manufacturers to supply through three authorized wholesalers and maintain cGMP and DSCSA compliance. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to assess vendor capacity for direct-to-manufacturer prescription programs, signaling exploratory procurement activity before formal solicitation.